Alex  Gorsky net worth and biography

Alex Gorsky Biography and Net Worth

Alex Gorsky is Executive Chairman of Johnson & Johnson, and one of just seven leaders to have served in the dual role of Chairman and Chief Executive Officer since the company was listed on the New York Stock Exchange in 1944.

Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next three decades, he advanced through positions of increasing responsibility in sales, marketing, and management, culminating in being named CEO and Chairman in 2012.

Under his leadership, Johnson & Johnson became an industry leader in areas including oncology, immunology, and digital surgery, and reimagined how one of the world’s most iconic companies could meet the healthcare needs of families around the globe. During Alex’s tenure, record levels of R&D investment, including $14.7 billion in 2021 alone, as well as hundreds of acquisitions and partnerships contributed to significant growth across its Medical Devices, Pharmaceutical, and Consumer Health sectors. As part of Johnson & Johnson’s commitment to serving more than a billion people each day, Alex also oversaw significant breakthroughs in public health, including the successful deployment of an Ebola vaccine in Africa and the development of the Janssen single-shot COVID-19 vaccine in just 13 months.

During Alex’s time as CEO, Johnson & Johnson was consistently recognized as one of the most innovative and best-managed companies in the world—featured on the list of Fortune’s Most Admired Companies in each year of his tenure, recognized as a “Most Innovative Company” by Fast Company, repeatedly named to Fortune’s “Change the World” list, and ranked as the #1 best-run healthcare company in The Wall Street Journal Management Top 250 since its inception in 2017. Alex continually promoted a more diverse and inclusive culture at Johnson & Johnson, serving as the driving force behind many of the company’s DE&I initiatives, including a $100 million pledge to fight health inequities faced by communities of color in the United States.

Outside Johnson & Johnson, Mr. Gorsky’s influence has shaped both the healthcare landscape and the greater business community through his work as a member of the Business Roundtable and the Business Council Executive Committees. Among other accolades, he has been honored with the Robert F. Kennedy Human Rights Ripple of Hope Award (2017), the Prix Galien Roy Vagelos Pro Bono Humanum Award (2021), the BENS Eisenhower Award for outstanding contributions to the United States (2021), the Franklin Institute Bower Award for Leadership (2022), and the Distinguished Graduate Award from the U.S. Military Academy at West Point (2022). Alex currently sits on the Board of Directors of Apple, IBM, NewYork-Presbyterian Hospital, the Travis Manion Foundation, and Wharton’s Board of Advisors.

After completing his undergraduate education at the U.S. Military Academy at West Point, Mr. Gorsky served six years in the Army, earning the rank of captain, the Ranger tab, and Airborne wings. He earned his MBA from Wharton in 1996. Alex has been married to his wife, Pat, for more than 30 years, and they are the parents to one son, Nick.

What is Alex Gorsky's net worth?

The estimated net worth of Alex Gorsky is at least $654,831.87 as of November 9th, 2020. Mr. Gorsky owns 4,231 shares of Johnson & Johnson stock worth more than $654,832 as of November 18th. This net worth estimate does not reflect any other investments that Mr. Gorsky may own. Learn More about Alex Gorsky's net worth.

How do I contact Alex Gorsky?

The corporate mailing address for Mr. Gorsky and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Alex Gorsky's contact information.

Has Alex Gorsky been buying or selling shares of Johnson & Johnson?

Alex Gorsky has not been actively trading shares of Johnson & Johnson during the last ninety days. Most recently, Alex Gorsky sold 264,465 shares of the business's stock in a transaction on Friday, November 16th. The shares were sold at an average price of $145.96, for a transaction totalling $38,601,311.40. Following the completion of the sale, the chief executive officer now directly owns 481,254 shares of the company's stock, valued at $70,243,833.84. Learn More on Alex Gorsky's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Chairman), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (EVP), Jennifer Taubert (EVP), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 3 times. They sold a total of 68,757 shares worth more than $10,308,224.54. The most recent insider tranaction occured on August, 30th when VP Robert J Decker sold 5,635 shares worth more than $930,113.10. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 8/30/2024.

Alex Gorsky Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2018Sell264,465$145.96$38,601,311.40481,254View SEC Filing Icon  
See Full Table

Alex Gorsky Buying and Selling Activity at Johnson & Johnson

This chart shows Alex Gorsky's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $154.77
Low: $152.35
High: $155.33

50 Day Range

MA: $161.11
Low: $151.86
High: $167.38

2 Week Range

Now: $154.77
Low: $143.13
High: $168.85

Volume

7,510,581 shs

Average Volume

7,018,732 shs

Market Capitalization

$372.63 billion

P/E Ratio

22.40

Dividend Yield

3.22%

Beta

0.53